Development of cancer therapy targeting the metabolism activated by EpCAM in cancer stem cells.
Project/Area Number |
24590389
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Pathological medical chemistry
|
Research Institution | Keio University |
Principal Investigator |
NAGANO Osamu 慶應義塾大学, 医学部, 講師 (30404346)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 癌幹細胞 / EpCAM / 糖代謝 / 代謝 |
Outline of Final Research Achievements |
In this study, I analyzed the role of EpCAM, one of the major cancer stem cell markers, in the metabolism of cancer stem cell to develop new cancer therapy selectively targeting cancer stem cells. As a result, I found that EpCAM expression promotes the activation of pentose phosphate pathway and thereby promotes the reduction of oxidized glutathione. These results suggested that the combination therapy using the inhibitors for pentose phosphate pathway and glutathione synthesis might be effective to EpCAM-expressing cancer stem cells.
|
Report
(4 results)
Research Products
(24 results)
-
[Journal Article] CD44s signals the acquisition of the mesenchymal phenotype required for anchorage-independent cell survival in hepatocellular carcinoma.2014
Author(s)
Okabe H, Ishimoto T, Mima K, Nakagawa S, Hayashi H, Kuroki H, Imai K, Nitta H, Saito S, Hashimoto D, Chikamoto A, Ishiko T, Watanabe M, Nagano O, Beppu T, Saya H and Baba H
-
Journal Title
Br J Cancer
Volume: 印刷中
Issue: 4
Pages: 958-66
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
[Journal Article] Gene expression profile of a newly established choriocarcinoma cell line, iC(3)-1, compared to existing choriocarcinoma cell lines and normal placenta.2013
Author(s)
Kobayashi Y, Banno K, Shimizu T, Ueki A, Tsuji K, Masuda K, Kisu I, Nomura H, Tominaga E, Nagano O, Saya H, Aoki D.
-
Journal Title
Placenta
Volume: 34
Issue: 2
Pages: 110-118
DOI
Related Report
Peer Reviewed
-
[Journal Article] xCT Inhibition Depletes CD44v-Expressing Tumor Cells That Are Resistant to EGFR-Targeted Therapy in Head and Neck Squamous Cell Carcinoma.2013
Author(s)
Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, Onishi N, Masuko T, Yoshizawa K, Kawashiri S, Mukai M, Asoda S, Kawana H, Nakagawa T, Saya H, Nagano O.
-
Journal Title
Cancer Research
Volume: 73
Pages: 1855-1866
Related Report
Peer Reviewed
-
[Journal Article] CD44s regulates the TGF-b-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma.2012
Author(s)
Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H, Watanabe M, Beppu T, Tamada M, Nagano O, Saya H, Baba H
-
Journal Title
Cancer Research
Volume: 72
Pages: 3414-3423
Related Report
Peer Reviewed
-
[Journal Article] Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell.2012
Author(s)
Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T,Mogushi K, Tanaka H, Osawa T, Kanki Y, et al
-
Journal Title
Nature Communications
Volume: 6;3
Issue: 1
Pages: 883-883
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-